Abbott has entered into a commercialisation agreement with Novo Nordisk India to market a second brand of semaglutide, ...

Zydus to launch Semaglutide Injection in India, featuring a unique reusable pen for improved diabetes and obesity management.

India’s diabetes burden is well known, but what’s less visible is the cardiac or heart risk that rides silently alongside it. With cardiovascular disease (heart disease) being the leading cause of ...

Indian drugmaker Dr Reddy's Laboratories is likely to launch its generic semaglutide injection in the country in March ‌under the brand name Obeda, according to two people ...

Abbott teams up with Novo Nordisk India to introduce Extensior, a second brand of Ozempic, aimed at treating type 2 diabetes in India. Utilizing Novo Nordisk's scientific expertise and Abbott's ...

One of the standout features of Zydus' semaglutide offering is its unique, indigenously developed drug delivery system ...

With patent protection on Danish multinational Novo Nordisk’s blockbuster GLP-1 diabetes drug semaglutide (Ozempic) set to ...

BENGALURU (Reuters) - India is planning to offer incentives to promote local manufacturing of GLP-1 drugs used to treat diabetes and obesity, in 2026, a top government official said on Friday. GLP-1 ...

Zydus plans to launch its diabetes and obesity injection using a reusable adjustable pen device after patent expiry, as more Indian drugmakers enter the market.

Abbott partners with Novo Nordisk to launch Extensior, a second Ozempic brand for type 2 diabetes management in India.

The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to ...

New data reveals rising abdominal obesity in India, with visceral fat increasing risks of type 2 diabetes, heart disease, and ...